1 / 27

THERAPY USING ANTIFUNGALS AND ANTIVIRALS

THERAPY USING ANTIFUNGALS AND ANTIVIRALS. Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu. CLASSIFICATION OF FUNGI. MOST COMMONLY ISOLATED SPECIES OF CANDIDA. C. albicans C. tropicalis C. parapsilosis C. kefyr

glenda
Télécharger la présentation

THERAPY USING ANTIFUNGALS AND ANTIVIRALS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. THERAPY USING ANTIFUNGALS AND ANTIVIRALS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu

  2. CLASSIFICATION OF FUNGI

  3. MOST COMMONLY ISOLATED SPECIES OF CANDIDA C. albicans C. tropicalis C. parapsilosis C. kefyr C. glabrata C. krusei C. guillermondii C. lusitaniae

  4. LONGİTUDİNAL STUDİES: A TEN-YEAR FUNGEMİA SURVEY Krcmery V Jr. et al. DMID 2000; 36: 7. Slovak Republic

  5. HISTORY OF ANTIFUNGAL DRUGS 1950s Nystatin Amphotericin B Griseofulvin 1960s Miconazole Clotrimazole 1980s Ketoconazole 1970s Flucytosine 1990s Fluconazole Itraconazole caps Itraconazole soln Terbinafine Lipid Ampho Micafungin Anidulafungin Posaconazole 2000s Caspofungin Voriconazole

  6. Good Fungicidal Broad spectrum Relatively inexpensive Not so good A few holes in coverage Complex pharmacokinetics Significant IRAEs Nephrotoxicity -glomerular -tubular Hematologic toxicity Difficult dosing AMPHOTERICIN B DEOXYCHOLATE

  7. SUMMARIZING THE AMPHO B LIPID FORMULATIONS • Possibly more effective than amphotericin B in certain circumstances (liposomal better than ABLC?) • Less toxic (IRAEs, kidney) • Liposomal amphotericin B is less toxic than ABLC • Expensive

  8. Cost in a 70 kg patient DAILY DOSE AMB (1 mg/kg) ABLC (5 mg/kg) L-AMB (5 mg/kg) THE HIGH COST OF LIPID AMPHO FORMULATIONS

  9. FLUCYTOSINE (5-FC) CP CD Intracellular 5-FC 5-FC 5-FU UMP PPase UPRTase 5’-fluorouridine monophosphate (FUMP) 5’-fluorodeoxyuridine monophosphate (F-dUMP) thymidylate synthase inhibitor inhibits DNA synthesis phos x2 5’-fluoro-UTP (FUTP) incorporated into RNA disrupts protein synthesis ENZYMES: CP = cytosine permease CD = cytosine deaminase UPRTase = uracil phosphoribosyl transferase UMP Ppase = UMP pyrophosphorylase

  10. Good Activated by fungal enzymes Unique mechanism of action Excellent tissue penetration Simple renal elimination Serum concentrations can be monitored Not so good Somewhat narrow spectrum Frequent dosing, large capsules Bone marrow suppression Hepatotoxicity Secondary resistance Expensive (about $6.30 per 500mg capsule) A SUMMARY OF FLUCYTOSINE

  11. AZOLE ANTIFUNGALS AVAILABLE IN THE US Four systemic drugs Ketoconazole (Nizoral) Fluconazole (Diflucan) Itraconazole (Sporanox) Voriconazole (Vfend) Topical butoconazole, clotrimazole, miconazole, terconazole, and tioconazole are all available for vulvovaginal candidiasis

  12. TOXICITIES AND DRUG INTERACTION POTENTIAL (EXCEPT VORI) Toxicity ketoconazole > itraconazole > fluconazole DI potential ketoconazole > itraconazole > fluconazole Pregnancy all topical azoles are considered safe (avoid systemic administration)

  13. ANTICANDIDAL ACTIVITY OF VORICONAZOLE C. albicans 0.015-0.5 C. parapsilosis 0.015-0.125 C. kefyr 0.015 C. tropicalis 0.03-1 C. glabrata 0.25-4 C. krusei0.25-2 C. lusitaniae 0.5 MIC90 Vori MICs tend to be higher for isolates with high fluconazole MICs The higher MICs of C. glabrata and C. krusei are of uncertain clinical relevance Matar et al. AAC 2003; 47: 1647; Chryssanthou et al. JCM 2002; 40: 3841; Laverdiere et al. JAC 2002; 50: 119; Pelletier et al. J Med Microbiol 2002; 51: 479; Pfaller et al. DMID 1999; 35: 19; Uzun et al. DMID 2000; 38: 101

  14. OTHER TIDBITS ABOUT VORICONAZOLE • Active vs C. neoformans, Trichosporon • Broadly active vs Aspergillus including A. terreus • Reasonably active for dimorphic fungi, but less so for Sporothrix • Active vs Fusarium • Cidal for Candida, static for Aspergillus (like caspofungin) • ZYGOMYCETES ARE NOT SUSCEPTIBLE

  15. VORICONAZOLE: DETAILS • 90% oral absorption, Tmax 2 h, take on empty stomach • Nonlinear kinetics • SS Vd 4.6 L/kg; CSF conc 29-68% of serum • Wide interpatient variability in plasma concentrations • Elimination t½ 6 hours • Metabolites eliminated in the urine; <5% of drug eliminated unchanged. Major metabolite: N-oxide. • Decrease dose in hepatic failure • Obesity: use total body weight • Weird side effect: visual disturbances • Dose: 6 mg/kg IV q12h x2 doses, then 4 mg/kg IV q12h (200 mg po q12h when appropriate to switch)

  16. VORICONAZOLE AND DRUG INTERACTIONS • Substrate and inhibitor of multiple cytochrome P450 enzymes (CYP2C9, CYP2C19, CYP3A4) • 2C19 is the major metabolizing enzyme; 3A4 is less important • 2C19 exhibits genetic polymorphism (e.g. 15-20% of Asians are expected to be slow metabolizers) • Voriconazole as the object drug: avoid rifampin and ritonavir • Vori as the precipitant drug: lots more to avoid. For example, sirolimus is contraindicated, but CSP and tacrolimus are ok if their doses are lowered.

  17. CASPOFUNGIN (CANCIDAS) our first echinocandin; “penicillin for fungi” Canuto MM & Rodero FG. The Lancet Infect Dis 2002; 2: 550

  18. CLINICAL USE OF CASPOFUNGIN • May become the drug of choice for invasive candidiasis, candidemia • Synergistic with voriconazole in vitro; in vivo data are scant but supportive for certain mold infections such as Aspergillus • Most common toxicities: infusion-related adverse effects, headache • Increased LFTs, especially in patients receiving cyclosporine (less with micafungin?) • Dose: 70 mg IV on day 1, then 50 mg daily (reduced for hepatic insufficiency). Infused over 1 hour in non-dextrose containing solution. • Cost: $300-400/day

  19. POSACONAZOLE (SCHERING-PLOUGH) • New broad-spectrum triazole • Active vs Candida, Trichosporon, Aspergillus, Fusarium, Mucor, Rhizopus • Vd 6 L/kg; 97-99% protein bound; T1/2 25 hr; glucuronidated, metabolites excreted in feces • Inhibits CYP3A4 • Common ADR: fever, GI • Dose: 200 mg po qid or 400 mg po bid • Oral BA 4x with high fat meal; susp is 35% more bioavailable than capsules; split dosing improves absorption

  20. IMPORTANT USES OF ANTIVIRAL DRUGS • INFLUENZA • HEPATITIS B AND C • HERPESVIRUS (HSV, VZV, CMV) • HIV (outside our scope for today) • MISCELLANEOUS (e.g. ribavirin for RSV)

  21. INFLUENZA DRUGS ARE SOMETIMES USEFUL IN OUTBREAK SITUATIONS • Not a substitute for vaccination • Amantadine and rimantadine are ineffective for influenza B • Treatment should begin within 2 days of symptom onset • Serious influenza-related complications are not prevented

  22. TREATMENT OF HEPATITIS B • ACUTE • No therapy recommended • CHRONIC • IFN-2b 5mu sq qd (or 10 mu sq tiw) x16 weeks • Lamivudine (Epivir) 100 mg po qd x1 year or more • Adefovir (Hepsera) 10 mg po qd

  23. TREATMENT OF HEPATITIS C • ACUTE • PEG-IFN + ribavirin as below, but remains controversial • CHRONIC • PEG-IFN-2a (Pegasys) 180 mcg sq q-week or -2b (Peg-Intron) 1.5 mcg/kg sq q-week PLUS oral ribavirin (genotype 1: 400 mg qam + 600 mg qpm if <75 kg, 600 mg po bid if >75 kg; genotype 2 or 3, 400 mg po bid regardless of weight)

  24. DRUGS FOR HERPESVIRUS • Herpes simplex virus (HSV), varicella-zoster virus (VZV) • Acyclovir • Famciclovir • Valacyclovir • Cytomegalovirus (CMV) • Ganciclovir • Valganciclovir • Foscarnet (toxic, avoid) • Cidofovir + probenecid (toxic, avoid)

  25. THANK YOU FOR ATTENDING MY PRESENTATIONS THIS QUARTER!

More Related